Want to join the conversation?
In 4Q15, $STJ posted sales of $580MM in its largest segment Cardiac Rhythm Management, down 15% from 4Q14. Atrial Fibrillation product sales fell 2% to $276MM. Cardiovascular sales fell 6% to $327MM while Neuromodulation product sales rose 3% to $128MM.
$WBA is yet to receive US anti-trust clearance for its Rite Aid acquisition. The deadline for the deal expires on January 27.
$BMY plunge 7.2%. No credits to the non-acceleration of approval for lung cancer combination treatment.